期刊
HUMAN VACCINES & IMMUNOTHERAPEUTICS
卷 16, 期 1, 页码 109-111出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2019.1636598
关键词
Acute myeloid leukemia; histamine dihydrochloride; IL-2; immunotherapy; relapse prevention; normal karyotype
资金
- Cancerfonden [CAN 2016/351]
- Vetenskapsradet [2016-01928]
- Swedish Research Council [2016-01928] Funding Source: Swedish Research Council
- Vinnova [2016-01928] Funding Source: Vinnova
Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据